Vela Diagnostics has announced provisional authorization from the Singapore Health Services Association (HSA) for its ViroKey™ SARS-CoV-2 RT-PCR Test. This allows the test to be supplied to healthcare institutions, private hospitals, medical clinics and clinical laboratories licensed under the Private Hospitals and Medical Clinics (PHMC) Act in Singapore.

The ViroKey™ SARS-CoV-2 RT-PCR Test is a probe-based reverse transcription PCR Test that detects SARS-CoV-2 by targeting conserved regions of the SARS-CoV-2 genome. The manual version of the assay enables quick adoption of the test by laboratories with existing Applied Biosystems 7500 Fast Dx (ABI 7500 Fast Dx) instruments.

For high-throughput testing, Vela Diagnostics has also developed a research use only (RUO) automated version of the test which is optimized for a workflow consisting of the Sentosa™SX101 instrument, in conjunction with the Sentosa™ SA201 instrument or the ABI 7500 Fast Dx.

The test is also pending CE marking.